登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance
ClinicalTrials.gov 上登记的一项肺癌开放试验,由中国医学科学院肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07842887,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or pathologically confirmed primary non-small cell lung cancer (NSCLC).
入选标准第 4 条
Previous treatment with a third-generation EGFR tyrosine kinase inhibitor, including but not limited to osimertinib, almonertinib, or furmonertinib, followed by radiographically confirmed disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
入选标准第 7 条
A confirmed sensitizing EGFR mutation, including but not limited to an exon 19 deletion or an exon 21 L858R mutation.
入选标准第 6 条
At least one measurable lesion according to RECIST v1.1.
入选标准第 10 条
Histologic transformation, such as transformation to small cell lung cancer.
排除标准第 3 条
Female participants of childbearing potential must have a negative pregnancy test and agree to use effective contraception during study treatment and for at least 1 month after the last dose of all-trans retinoic acid.
入选标准第 12 条
Pregnant or breastfeeding, or planning pregnancy or conception during the study.
排除标准第 14 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07842887,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily provides written informed consent and agrees to comply with the study requirements. Aged 18 years or older, with no restriction based on sex. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Participants with an ECOG performance status of 2 may be enrolled at the investigator's discretion. Histologically or pathologically confirmed primary non-small cell lung cancer (NSCLC). Stage IV disease according to the eighth edition of the American Joint Committee on Cancer/Union for International Cancer Control TNM staging system, or recurrent or metastatic NSCLC that is not suitable for curative local treatment. A confirmed sensitizing EGFR mutation, including but not limited to an exon 19 deletion or an exon 21 L858R mutation. Previous treatment with a third-generation EGFR tyrosine kinase inhibitor, including but not limited to osimertinib, almonertinib, or furmonertinib, followed by radiographically confirmed disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). Disease progression after at least one standard systemic treatment following resistance to a third-generation EGFR tyrosine kinase inhibitor, or inability to tolerate or unsuitability for currently available standard treatment, as determined by the investigator. No clearly available and appropriate standard targeted therapy option, as determined by the investigator. At least one measurable lesion according to RECIST v1.1. Adequate major organ function to receive the study treatment, as determined by the investigator. Female participants of childbearing potential must have a negative pregnancy test and agree to use effective contraception during study treatment and for at least 1 month after the last dose of all-trans retinoic acid. Able to understand and comply with the study requirements, as determined by the investigator.排除标准:Exclusion Criteria:
History of another malignancy, except for a malignancy that has been clinically cured and is considered by the investigator to have a low risk of recurrence. Uncontrolled brain metastases, leptomeningeal metastases, or a central nervous system lesion requiring urgent local treatment. Histologic transformation, such as transformation to small cell lung cancer. Uncontrolled acute or chronic infection, or an active infection requiring systemic anti-infective treatment. Active tuberculosis. Positive human immunodeficiency virus antibody test, active hepatitis B, or active hepatitis C. Active autoimmune disease, or a history of autoimmune disease requiring systemic immunosuppressive treatment. A history of a Grade 3 or higher immune-related adverse event following treatment with an immune checkpoint inhibitor, or permanent discontinuation of immunotherapy because of immune-related toxicity. Severe or uncontrolled cardiovascular or cerebrovascular disease. An unstable thrombotic or bleeding event requiring therapeutic intervention within 6 months before screening. Clinically significant uncontrolled hyperlipidemia, particularly markedly elevated triglycerides, that may increase the risks associated with all-trans retinoic acid treatment, as determined by the investigator. Uncontrolled Grade 2 or higher hepatic dysfunction, or underlying liver disease that may substantially increase the risk of ATRA-related hepatotoxicity, as determined by the investigator. History of a severe hypersensitivity reaction to all-trans retinoic acid, another retinoid, tislelizumab, or any component of these products. Pregnant or breastfeeding, or planning pregnancy or conception during the study. Previous or current benign intracranial hypertension or pseudotumor cerebri. Current treatment with a tetracycline that cannot be discontinued. Current treatment with another anticancer therapy or investigational product without completion of the protocol-required washout period. Any other condition that, in the investigator's opinion, makes the individual unsuitable for participation in the clinical trial.
引自 ClinicalTrials.gov, NCT07842887, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07842887,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。